[{"orgOrder":0,"company":"Dexcom","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Dexcom Team Up on New Program to Help Improve Diabetes Management","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dexcom","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dexcom \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Dexcom \/ E.."},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ N.."},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ N.."},{"orgOrder":0,"company":"Cipla","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla to sell Eli Lilly's Insulin Products Humalog, Trulicity in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cipla \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ El.."},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia\u2019s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone\u00ae Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Do.."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics\u2019 Partner Receives Approval for Human Insulin for IV Infusion","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Baxter Healthcare Corporation","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Biocon Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Baxter Hea.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly to Acquire Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sigilon Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."}]

Find Clinical Drug Pipeline Developments & Deals for Humalog

Humalog
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Humalog

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

13 API Suppliers, 7 USDMF, 5 JDMF, 1 Listed Suppliers

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

FINISHED DOSAGE FORMULATIONS

117 FDF Dossiers, 3 FDA Orange Book, 78 Europe, 16 Canada, 4 Australia, 15 South Africa, 1 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Pfanstiehl, 3 Actylis, 1 BioSpectra, 1 Kerry, 1 Pluviaendo

EXCIPIENTS BY APPLICATIONS

6 Parenteral, 2 Topical, 1 Film Formers & Plasticizers, 1 Coating Systems & Additives, 1 Controlled & Modified Release

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 73 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 58 Finished Drug Prices, 12 Annual Reports

MARKET PLACE

3 APIs, 2 FDF Dossiers

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 3 JP, 2 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Mannkind

U.S.A

Formnext Forum

Not Confirmed

02

Sigilon Therapeutics

U.S.A

Formnext Forum

Not Confirmed

03

Mannkind

U.S.A

Formnext Forum

Not Confirmed

04

Baxter Healthcare Corporation

U.S.A

Formnext Forum

Not Confirmed

05

Tonghua Dongbao Pharma

China

Formnext Forum

Not Confirmed

06

Cipla

India

Formnext Forum

Not Confirmed

07

Adocia

France

Formnext Forum

Not Confirmed

08

Adocia

France

Formnext Forum

Not Confirmed

09

Dexcom

U.S.A

Formnext Forum

Not Confirmed